Advertisements



Allergan pursuit of longer-acting toxin not a risk for Revance, says Cowen

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 14th, 2018

Seattle Genetics risk/reward favorable ahead of ASH, says Cowen

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 16th, 2018

Drug stocks are "no longer" reliable safety nets for investors: Cramer

Jim Cramer issues a warning to investors about the pharmaceutical sector, which includes high-profile stocks like Allergan and Gilead......»»

Category: topSource: madmoneyNov 1st, 2018

Higher rates: Sign of economic strength or a risk? Try both

This week's dizzying sell-offs in the financial markets have been a rude reminder that the U.S. economy is no longer relying on ultra-low interest rates to fuel growth......»»

Category: topSource: foxnewsOct 11th, 2018

Higher rates both a sign of US economic might and risk to it

This week's dizzying sell-offs in the financial markets have been a rude reminder that the U.S. economy is no longer relying on ultra-low interest rates to fuel growth. .....»»

Category: topSource: moneycentralOct 11th, 2018

Higher rates both a sign of US economic might and risk to it

This week's dizzying sell-offs in the financial markets have been a rude reminder that the U.S. economy is no longer relying on ultra-low interest rates to fuel growth. .....»»

Category: topSource: moneycentralOct 11th, 2018

"We Have Really Lost Our Way" - Trader Laments Market"s Risk Ignorance

"BTFD", "Goldilocks", "Climbing a wall of worry", "Powell Put", "Trump Put", "It's different this time." The excuses to buy stocks - no matter what headline tape bomb explodes - grow longer and more desperate as asset-gatherers and commission-.....»»

Category: blogSource: zerohedgeSep 28th, 2018

Revance selloff on Allergan data a buying opportunity, says Mizuho

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 27th, 2018

Red Hat remains well positioned over medium to longer-term, says Cowen

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 20th, 2018

JMP: Changing Competitive Landscape Makes Revance Less Appealing

Revance Therapeutics Inc (NASDAQ: RVNC), a biotech company developing a botulinum toxin product, could face a competitive backlash, according to JMP Securities. Latest Ratings for RVNC Dat.....»»

Category: blogSource: benzingaSep 17th, 2018

Revance downgraded to Market Perform after Allergan data at JMP Securities

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 17th, 2018

Alnylam data publication points to positive Onpattro risk profile, says Cowen

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 14th, 2018

Revance shares defended at Cowen

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 14th, 2018

Pivotal: Snap No Longer A Sell, But Stock Could Still Fall

Shares of social media company Snap Inc (NYSE: SNAP) briefly fell below $9 per share Wednesday and are now trading at a more balanced risk-reward profile for the longer-term, according to Pivotal Research Group.  Lates.....»»

Category: blogSource: benzingaSep 13th, 2018

Cowen downgrades Westlake Chemical to Market Perform on heightened margin risk

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 7th, 2018

Tesla CEO Musk drops pursuit of $72 billion take-private deal

Tesla Inc CEO Elon Musk said late on Friday he would no longer pursue a $72 billion deal to take his U.S. electric car maker private, abandoning an idea that had stunned investors and drawn regulatory scrutiny......»»

Category: topSource: reutersAug 25th, 2018

L Brands downside risk may persist, says Cowen

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 24th, 2018

J. Jill downgraded as earnings at risk from changes to product and marketing

J. Jill Inc. was downgraded to market perform from outperform at Cowen & Co. with analysts seeing a risk to earnings from the changes to product, mark.....»»

Category: topSource: marketwatchAug 22nd, 2018

P&G Raises Prices to Improve Margins

Strategy is fraught with risk as products may no longer command premium pricesRelated Stocks: PG,.....»»

Category: worldSource: nytAug 7th, 2018

People who sleep for longer than 8 hours could have a greater risk of dying early — but that doesn"t mean you should never sleep in

Nelli Syrotynska / Shutterstock A new study has shown too much sl.....»»

Category: topSource: businessinsiderAug 7th, 2018

Qualcomm"s Risk-Reward Is Too Favorable to Ignore, Cowen Says In Upgrade

With QUALCOMM, Inc. Latest Ratings for.....»»

Category: blogSource: benzingaAug 6th, 2018